CLN-617

· Cullinan Therapeutics

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CLN-617, covering 2025-03-03 to 2025-03-03. Get the full timeline:

Most recent: Clinical Trial Update: CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors [Phase 1]